Cowen Starts Janux Therapeutics (JANX) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
BofA Securities Starts Janux Therapeutics (JANX) at Buy
July 6, 2021 8:21 AM EDTBofA Securities analyst Geoff Meacham initiates coverage on Janux Therapeutics (NASDAQ: JANX) with a Buy rating and a price target of $35.00.
The analyst commented, "We initiate coverage on Janux Therapeutics with a Buy rating and a $35 PO. Janux is an oncology-focused company... More



